Veriheal

NOVEMBER 30, 2021

Always consult a physician before attempting alternative therapies. In 2008, he published psychedelic safety guidelines. He conducted the first blinded human research study into the psychoactive effects of salvinorin A in 2011 and published data on MDMA pill testing services in 2017.

Research and Development 96

Research and Development Therapy Data Treatment 96

Cannabis Law Report

JANUARY 12, 2022

According to a recent report released by the Psychedelic Science Funders Collaborative, “Oregon’s psilocybin therapy program provides a high-quality model for psychedelic healing in a non-prescription context that could be replicated in other states.”

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

Cannabis Law Report

DECEMBER 2, 2021

The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021. IGC) engages in the development of cannabinoid-based therapies for healthcare applications. million individuals in the U.S.

Clinical Trials 52

Clinical Trials Data Patients THC 52

Cannabis Law Report

OCTOBER 9, 2021

Data from the Denver District Attorney’s office shows only 47 cases related to psychedelic mushrooms since May 2019 decriminalization. This report to the best of our ability clearly demonstrates decriminalizing has not resulted in any significant public health or safety issues,” Matthews told The Denver Post. The Denver Post reports.

Decriminalization 52

Decriminalization Law Data Safety 52

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. This is the largest trial ever conducted in psilocybin therapy, and it was done amid the lockdowns and challenges of the COVID pandemic. million, or $0.79 million, or $2.61

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Veriheal

DECEMBER 15, 2021

Published in the Journal of Medical Internet Research, the fresh data suggests that the cannabinoids found in cannabis, such as THC and CBD , may have potential as a treatment for sleep deprivation. The post Cannabinoids May Promote a Good Night’s Sleep, Study Finds appeared first on Cannabis Central.

Sleep 95

Sleep Cannabinoids Therapy Treatment 95

Cannabis Law Report

OCTOBER 13, 2021

But despite increasing acceptance by the public, and commercial investment in psychedelic therapies, aging federal laws stem the flow of vital research. An abundance of science and public health data supports it. Psilocybin, a compound produced by many species of fungi, is one of the most well-studied psychedelics.

Research and Development 52

Research and Development Therapy Access Data 52

MMJ Recs

NOVEMBER 17, 2023

Promoting Research and Innovation The medical marijuana industry promotes research and innovation in the field of cannabis-based therapies. Research and Innovation: Maryland’s MMJ program encourages research and innovation in the field of cannabis-based therapies, benefiting patients both in the state and nationwide.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Veriheal

JUNE 30, 2023

Researchers say this emphasizes just how important it is that psilocybin therapy be done in a controlled setting with therapy and community-based after-care. The 14-page document covers several aspects of the drug development process, including trial best practices, data collection, and new drug application requirements.

Clinical Trials 92

Clinical Trials Research and Development Therapy Policy 92

Cannabis Law Report

NOVEMBER 11, 2021

The initiative also created the Denver Psilocybin Policy Review Panel (“Panel”), which was required to report back to the City on the public safety and other impacts of decriminalization. There have been no significant negative impacts on public safety as a result of decriminalizing psilocybin possession in the City of Denver.

Policy 52

Policy Decriminalization Safety Therapy 52

Cannabis Law Report

MAY 26, 2022

Successful Behavioral Addiction Study Supplied Data for Patent. The successful completion of Awakn’s behavioral addictions study was announced last week and the data provided from the study was used in the patent filing. The treatment was also well tolerated with no safety concerns. Awakn Life Sciences Corp. (

Treatment 52

Treatment Research and Development Therapy Data 52

Cannabis Law Report

SEPTEMBER 23, 2021

BIMA was an Open-label safety, tolerability and proof-of-concept study to investigate the role of MDMA-Assisted Psychotherapy in treating patients with alcohol use disorder (AUD). This data will assist Awakn’s progress by enabling a better design and more efficient execution of its clinical program. About Imperial College London.

Research and Development 52

Research and Development Therapy Treatment Data 52

Cannabis Law Report

JUNE 7, 2021

The Data and Safety Monitoring Committee (“DSMC”) for IGC’s clinical trial, having reviewed the data obtained through Cohort 1 and Cohort 2, recommended progressing to Cohort 3, which consists of administering three doses per day. This Phase 1 trial is currently testing IGC-AD1 for safety. www.igcinc.us

Clinical Trials 105

Clinical Trials Patients THC Safety 105

Cannabis Law Report

JUNE 12, 2021

“The data was showing that psychedelics were providing benefits to people suffering from anxiety, depression, addiction and PTSD. ” Parker helped Courtney book into the stateside clinic offering psychedelic therapy and she received five rounds of intravenous ketamine therapy. .

Therapy 105

Therapy Treatment Medicine Sleep 105

Cannabis Law Report

DECEMBER 16, 2019

Emerald Clinics captures clinical data from patients to generate evidence for the safety and efficacy of cannabis medicines. Emerald Clinics operates a network of four medical clinics around Australia, focused on providing care for patients who have exhausted conventional therapies and might be suitable for cannabinoid-based medicines.

Medicine 59

Medicine Data Safety Therapy 59

Canna Law Blog

DECEMBER 16, 2021

Psilocybin research license, which will allow the testing potency, conducting clinical investigations, researching efficacy and safety, and agricultural research. Psilocybin therapy is a breakthrough avenue for providing people with treatment for these ailments.

Legislation 96

Legislation Treatment Therapy Conditions 96

Cannabis Law Report

JANUARY 31, 2022

The SAP is a federal program that allows healthcare professionals to apply for access to non-marketed medications that have not yet been approved for sale, when such medications show clinical evidence of safety and efficacy and are intended to treat patients with a severe or life-threatening illness.

Research and Development 52

Research and Development Clinical Trials Packaging Access 52

Cannabis Law Report

DECEMBER 11, 2021

The clinic established the UK Medical Cannabis Registry to offer patients medical cannabis products at a reduced price while collecting and analysing clinical data from real-world evidence “to expand our understanding of medical cannabis in the UK”. The Sapphire Access Scheme will be open to an additional 2,000 patients in the UK.

Access 52

Access Patients Chronic Pain Treatment 52

The Cannigma

FEBRUARY 2, 2021

Medical cannabis was legally approved in Germany in 2017 when approval was given for therapy-resistant symptoms in severely affected patients independent of diagnosis and without clinical evidence-based data,” lead investigator Professor Carsten Buhmann of the University Medical Center Hamburg-Eppendorf explained in a statement.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

Veriheal

OCTOBER 29, 2020

Of that, the American National Institute on Drug Abuse (NIDA) has invested just over $1 billion and has allocated far more money to researching cannabis misuse and the negative effects of consuming cannabis and its compounds as a form of therapy. The data for this graphic was provided by Jim Hudson at Hellth.com. . Canada, and the U.K)

Pharmaceutical 98

Pharmaceutical Therapy Cannabinoids Chronic Pain 98

Cannabis Law Report

JULY 8, 2021

The intended purpose of these studies is to provide data that will feed into the cbdMD Therapeutics research pipeline. This safety data will support the ensuing preclinical trials in humans to explore the efficacy of the cannabinoids.

Research and Development 111

Research and Development Pets Cannabinoids eCommerce 111

SpeedWeed

MARCH 5, 2021

The investigators then performed an analysis of the data to quantify the relationships between lifetime cannabis use, 12-month cannabis use, and 12-month cannabis use frequency (at least monthly use and less than monthly use) and incidence of hypertension.

Blood Pressure 52

Blood Pressure Marijuana Data Therapy 52

Canna Law Blog

APRIL 13, 2019

These products have not been shown to be safe or effective, and deceptive marketing of unproven treatments may keep some patients from accessing appropriate, recognized therapies to treat serious and even fatal diseases.”. Specifically, the agency fears that.

CBD 90

CBD Safety Topical Food 90

Veriheal

APRIL 11, 2022

We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds. This means that U.S. We could potentially develop north of 11,000 drugs that are cannabinoid-based.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Puff Puff Post

MARCH 10, 2020

INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. About INM-755: INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

The Cannigma

JULY 1, 2022

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. Additionally, there are misleading practices of “p-hacking” where researchers can manipulate data through different statistical tests (thanks to modern computer programs) looking for statistically significant findings.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Cannabis Law Report

SEPTEMBER 15, 2021

This deceptive marketing of unproven treatments raises significant public health concerns because patients and other consumers may use them instead of approved therapies to treat serious and even fatal diseases. Thus, historical use of cannabis cannot be relied upon in establishing a level of safety for these products in humans.

THC 105

THC Pets Events Hemp 105

Cannabis Law Report

JUNE 7, 2021

1.526 were reduced as expected and consistent with other CDC-reported data on vaccine-induced antibody neutralization against these variants 1. The study showed neutralizing antibody titers against B.1.1.7 were not significantly impacted, while neutralizing antibody titers against P1 and B.1.526 Dr. James A.

Clinical Trials 64

Clinical Trials Research and Development Therapy Supply Chain 64

Cannabis Law Report

AUGUST 10, 2021

GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older. Prevalence and incidence of rare diseases: Bibliographic data.

Pharmaceutical 98

Pharmaceutical Treatment Epilepsy Research and Development 98

Cannabis Law Report

MAY 29, 2022

FDA granted Breakthrough Therapy designation for Spravato in 2013 and ultimately approved it for adults who have not responded to treatment after trying other antidepressant medications. More recently, MDMA therapy has inched closer to FDA approval. 10] In the meantime, FDA has approved some requests for compassionate use. [11].

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

TheAnswerPage

JANUARY 11, 2022

As a result, state medical marijuana rules and regulations have focused on the demands of the public without putting significant emphasis on the scientific data or the ability of the medical community to support and care for medical marijuana patients. Who monitors their health and the long-term effects of the marijuana therapy?

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

NOVEMBER 9, 2021

We find LinearDNA to be an excellent platform for CAR T-cell therapy development.”. These manufacturing complexities have likewise hindered research on CAR T-cell therapies. Dr. James A. About LineaRx, Inc.,

Clinical Trials 52

Clinical Trials Research and Development Therapy Supply Chain 52

CannaMD

SEPTEMBER 10, 2020

Is it safe to continue cannabis-based therapies during pregnancy? This creates a somewhat confusing landscape for mothers who might benefit from cannabis-based therapies, but are also concerned for the safety of their child and the very real possibility of institutional intervention when marijuana use during pregnancy is documented.

Marijuana 59

Marijuana Therapy Data THC 59

Cannabis Law Report

JUNE 2, 2021

Aggregate testing results will be reported to the director of the summer camp via safeCircle’s integration with CLEARED4, the Company’s pooled surveillance testing program partner, through CLEARED4’s smartphone-based online health safety management and reporting solution. Testing will be conducted from mid-June through end-July.

Clinical Trials 82

Clinical Trials Therapy Research and Development Collective 82

Veriheal

OCTOBER 14, 2021

Department of Transportation (DOT) Federal Motor Carrier Safety Administration (FMCSA), commercial drivers love cannabis. Recent data from the FMCSA showed that 98% of failed drug and alcohol screenings by licensed commercial drivers in the first half of 2020 were for drugs rather than alcohol. Drivers Love It; Policies Prohibit It.

Blood Pressure 90

Blood Pressure Therapy Cannabis Policy 90

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. Food and Drug Administration clearance of its Investigational New Drug (IND) application for the Phase 2 trial of MYMD-1 as a therapy for delaying aging and prolonging healthy lifespan. a driver of chronic inflammation.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

NOVEMBER 22, 2019

“Patients will benefit from cGMP-quality therapies in an accessible and efficient format.”. “MMJ clinical trials will provide the necessary data to prove that cannabis can treat essential tremors, a neurological disorder that causes involuntary shaking.” Most recently the FDA awarded MMJ International Holdings ?Orphan

DEA 66

DEA Clinical Trials THC Research and Development 66